Improvements in diagnostics for the early detection of Alzheimer's disease have the potential to transform patient care and ...

For small pharmas and biotechs approaching a commercial launch, agility and execution are more valuable than waiting for a ...

Attorney James Gourley details the many legal issues surrounding the GLP-1 drug market and offers advice to companies on how ...

In a follow up to his recent appearance on the Business of Biotech, Tolga Tanguler explains how Alnylam is positioning ...

On this week's episode of the Business of Biotech, Dr. Mark Eisner, EVP and Chief Medical Officer at Vir Biotechnology, talks about the company's post-COVID pivot into infectious diseases (Hepatitis ...

On today's episode, Tolga Tanguler, EVP and Chief Commercial Officer at Alnylam Pharmaceuticals, talks about commercializing RNAi therapies, how they fit into health insurance reimbursement systems, ...

In this episode of Cell & Gene: The Podcast, Host Erin Harris sits down with Peter Altman, Ph.D., CEO of BioCardia, to discuss the company’s evolution from a cardiac biotherapeutic delivery firm to a ...

The rise in use of GLP-1 medications is driving a convergence between pharmaceutical therapies and consumer health and wellness offerings, including real-world data collection and behavior management.

Essential medicines play a vital role in America’s health, and the supply is closely monitored by the FDA and industry groups. These medicines sustain life, provide life support and/or the prevention ...